Tower Research Capital (TRC)’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
VCM
MCM
TSC
PCM
Tower Research Capital (TRC)'s LUCD Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Lucid Diagnostics (LUCD) stake by 96% in Q1 2026, buying an estimated $12K and bringing the position to 19,127 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #3416.
Tower Research Capital (TRC) first reported a position in LUCD in Q4 2021 and has held it in 17 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.
- Tower Research Capital (TRC) held 19,127 shares of Lucid Diagnostics worth $22K as of Q1 2026.
- Tower Research Capital (TRC) bought 9,392 Lucid Diagnostics shares in Q1 2026, an estimated $12K.
- Lucid Diagnostics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3416 holding.
- Tower Research Capital (TRC) first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 17 quarters since.
- 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.